Home
>
US Stocks
>
KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals Inc
KALV

KalVista Pharmaceuticals Inc (KALV)

$16.7815.59%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
16.92
Today Low/High
16.62 / 16.94
52 Week Low/High
$11.64 / $45
P/E ratio
-12.3176
Market Cap
$466.49M

Company Details

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 clinical trial expected to initiate in the second quarter of 2021. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
Organisation
KalVista Pharmaceuticals Inc
Headquaters
Cambridge, Massachusetts, US
Employees
56
Industry
Health Technology
CEO
Thomas Crockett

Discover more

Frequently Asked Questions

What is KalVista Pharmaceuticals Inc (KALV) share price today?

Can Indians buy KalVista Pharmaceuticals Inc (KALV) shares?

How can I buy KalVista Pharmaceuticals Inc (KALV) shares from India?

Can Fractional shares of KalVista Pharmaceuticals Inc (KALV) be purchased?

What are the documents required to start investing in KalVista Pharmaceuticals Inc (KALV) stocks?

We are a SEBI registered investement advisor